Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
about
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.Aberrant expression of ALK and EZH2 in Merkel cell carcinomaMerkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune TherapyAvelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA.A perspective on the impact of radiation therapy on the immune rheostat.Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA In Situ Hybridization Assay.Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma.Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.Merkel Cell Carcinoma Therapeutic Update.Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma.Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform.The Emerging Role of TRAF7 in Tumor Development.Targeting neoantigens to augment antitumour immunity.Merkel cell polyomavirus and Merkel cell carcinoma.Merkel Cell Carcinoma of the Head and Neck: Recommendations for Diagnostics and Treatment.Molecular Profiling of Multiple Primary Merkel Cell Carcinoma to Distinguish Genetically Distinct Tumors From Clonally Related Metastases.Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection.Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.Higher Expression of Activation-induced Cytidine Deaminase Is Significantly Associated with Merkel Cell Polyomavirus-negative Merkel Cell CarcinomasMetastatic Merkel cell carcinoma response to nivolumab.Merkel Cell Polyomavirus: A New DNA Virus Associated with Human Cancer.Genomic analysis of atypical fibroxanthoma.Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe.Merkel cell carcinoma patients presenting without a primary lesion have elevated markers of immunity, higher tumor mutation burden and improved survival.Merkel cell carcinoma in the age of immunotherapy: Facts and hopes.Are there multiple cells of origin of Merkel cell carcinoma?Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC.Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics.Avelumab and other recent advances in Merkel cell carcinoma.PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma.Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy.A Monoclonal Antibody to SV40 Large T Antigen (PAb416) Does Not Label Merkel Cell Carcinoma.MGMT promoter methylation status in Merkel cell carcinoma: in vitro versus invivo.Cabozantinib in Patients with Advanced Merkel Cell Carcinoma.Targeting Merkel cell carcinoma by engineered T cells specific to T-antigens of Merkel cell polyomavirus.Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy.
P2860
Q27853379-D55988E6-ADF0-48AD-BDBD-CA42E24CD5BBQ36328692-FD8E5295-7F87-467F-82C2-CE6A3B13450FQ37117867-534F32F3-4325-4A79-9887-BAAFEFD25E0FQ38378516-091E0545-E2A4-4BB7-BF97-8F18FD29192FQ38611235-FDE4431C-53D6-4433-8AE9-C4CDA91A01FAQ38671851-8EEB799C-33C5-424F-8723-D5AE5987AB59Q38679488-986DC38A-444F-4C27-BE85-3C6F5D005B63Q38729084-336FD656-F3E3-46E1-BDCE-BFA4B44507F4Q38738614-D7DBA23E-50B6-4780-95B0-C87832B6D917Q38855013-A53203C5-A18A-42AE-8A54-DDA48D55ECBEQ38855025-2C30C835-260A-466C-923A-5BD0E96AF7D2Q38868829-FDA45E12-46AB-4324-A84B-E6A74FB09130Q38887303-F157289A-363A-4C5C-93F1-4327F179FE20Q38904371-C4E33791-51A8-4CF6-A60E-DC84A3903A2CQ38997320-0AE46C3C-B53A-4D80-BA54-E072F164BA8AQ39149196-0EB31EDB-8A4D-4470-BEEA-82A86BF2E2C8Q40046580-A11E2C8C-861B-4A0E-97A6-868BCAFAE3CBQ40100093-1C5B1478-2124-4372-ACB1-DCB9A80110C8Q40245609-B3E289F6-32DD-4B2D-BF78-15BEC774B808Q40463395-106C6DFB-B46C-473F-A3AF-0A30A0AA81A7Q41133627-29C2BDB3-DEB3-471C-A345-CBBC7ED79E96Q41681717-17CA199E-E569-4C40-81FF-822BE0C84613Q42368667-804D357F-01B6-46E5-884B-C9D3AFDB68F4Q45325990-95A9B372-D0F7-4B0F-BD08-FDFC50233553Q46176867-5670EB13-C836-4441-9ECC-1B6815B9DA67Q47114351-9C680856-9771-44C7-A873-D6564AA6CDFEQ47300122-2065084E-75E3-4F5A-A29F-E0F10A57C4C1Q47348356-7B7DA8FD-4BD8-4B2E-B597-370AF9B7ACFBQ47555708-099CBDC9-A990-4DA5-A498-ACD3CD10FC71Q47571383-54743793-5A7B-4D8E-896A-7A0CB65D0F16Q47584286-DC2B8AC8-8316-43E8-89E3-CCAA4F478C3BQ47658993-D3C7B56D-0945-4233-9735-BF52D0C39B8FQ47915808-BA382B6A-0A4D-4E39-B062-8214387E5A68Q49664880-22B1BC87-25AA-48C9-961E-75240D4698DDQ50060650-10399ECA-05CE-470A-863E-687EF4852BD5Q50071669-5D6F82B5-EF80-46E3-A683-4C5F1CD41DC9Q51061357-2FF52EE6-14C2-4354-8DFE-48BE0B8AEB28Q51751201-0131C3BA-C652-4D08-92E8-9806DA6344E1Q52804789-1CC33A37-EF15-4790-99C3-1B7559C89588Q53358653-977419E1-602C-48AB-AC8A-0EFAD3C1BE86
P2860
Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Mutational landscape of MCPyV- ...... mplications for immunotherapy.
@en
Mutational landscape of MCPyV- ...... mplications for immunotherapy.
@nl
type
label
Mutational landscape of MCPyV- ...... mplications for immunotherapy.
@en
Mutational landscape of MCPyV- ...... mplications for immunotherapy.
@nl
prefLabel
Mutational landscape of MCPyV- ...... mplications for immunotherapy.
@en
Mutational landscape of MCPyV- ...... mplications for immunotherapy.
@nl
P2093
P2860
P50
P356
P1433
P1476
Mutational landscape of MCPyV- ...... implications for immunotherapy
@en
P2093
Astrid Blom
Gerald Goh
Jonathan Levinsohn
Krista Stafstrom
Lola Yelistratova
Paul Nghiem
Richard P Lifton
Ryan Doumani
Timothy A Chan
Trent Walradt
P2860
P304
P356
10.18632/ONCOTARGET.6494
P407
P577
2016-01-01T00:00:00Z